

28 October 2026

Enlitic Builds Recurring Revenue with New Ensign Contract in Arizona

- **Three-year contract valued at US\$144,000 (~A\$206k¹) signed with Arizona-based Southwest Medical Imaging (SMIL), a US-based radiology provider, for Ensign's Hanging Protocols application, subject to successful validation.**
- **Enlitic continues to build commercial momentum, securing seven recurring revenue contracts across the USA, Australia and New Zealand since March 2026.**
- **Ensign contracts secured in CY2026 represent ~US\$830,000 in total contract value, establishing a growing base of contracted recurring revenue with potential opportunities for further expansion.**
- **Pipeline of new Ensign contract opportunities is strong and aided by the recent launch of Ensign v2.3.**

Please view the announcement here on our website: <https://enlitic.com/link/PwEKpe>

Healthcare technology company Enlitic, Inc. (ASX: ENL) ("Enlitic" or the "Company") has signed a three-year agreement with Southwest Medical Imaging ("**SMIL**"), an Arizona-based radiology provider, for its Ensign technology, adding to the Company's growing base of contracted annualised recurring revenue ("ARR").

This represents Enlitic's fifth Ensign customer agreement in the US market this calendar year, alongside contracts secured in Australia and New Zealand (see table below). It demonstrates Enlitic's strategy of securing targeted SaaS subscriptions with scope for additional applications, sites and workflows. The October 2026 release of Ensign v2.3 further broadens that opportunity by expanding the available commercial applications and supported imaging environments.

SMIL is another example of Enlitic expanding its customer base and technology footprint, particularly in the large United States market. Southwest Medical Imaging (SMIL) is a physician-owned and physician-led radiology practice in Arizona with 17 outpatient centres across the Phoenix metro area, Scottsdale, Mesa, Gilbert, Peoria, Paradise Valley, and Fountain Hills.

¹ Converted based on a USD:AUD exchange rate of 0.70

SMIL will use Ensign alongside its Intelrad PACS to standardise medical imaging data and improve the accuracy of automated Hanging Protocols. By reducing the need for radiologists to manually adjust image layouts, the solution is designed to improve workflow efficiency and consistency.

Contract Terms

The contract has a three-year term with a total subscription value of US\$144,000, equivalent to US\$48,000 annually, and provides an enterprise licence for unlimited studies. Following the initial three-year term, the contract automatically renews for successive one-year periods unless terminated in accordance with the agreement's terms including upon SMIL's notice.

The contract includes an initial validation phase. Annual subscription fees become payable upon confirmation that Ensign delivers at least a 15% improvement in radiologist workflow efficiency, measured using radiology reporting workflow data. The initial validation will assess workflow improvements across five neuroradiologists using SMIL's outpatient imaging studies.

Expanding adoption across the Intelrad customer base

The SMIL agreement adds to Enlitic's growing portfolio of customers operating within the Intelrad ecosystem. It demonstrates the application of Ensign to a specific operational challenge within radiology, supporting Enlitic's strategy of expanding adoption through targeted use cases that deliver measurable customer benefits.

It also follows the recent launch of Enlitic's Ensign v2.3 (*refer ASX Announcement 6 October 2026*), which expands the platform's commercial applications from eight to 12, including additional analytics, archive standardisation and workflow capabilities. Existing customers can adopt additional applications through separate subscriptions, supporting Enlitic's land-and-expand strategy and ability to steadily build its ARR base.

The release also introduced integration with Sectra systems alongside Intelrad. These integrations allow Ensign to operate within established medical imaging environments, broadening potential customer reach and providing more routes to deployment. Additional functionality and integrations create opportunities for ARR growth, subject to customer adoption and commercial agreement.

Enlitic CEO Michael Sistenich said: *"We are delighted to welcome SMIL as an Ensign customer, providing further validation of the technology and its growing adoption by leading radiology organisations. Securing seven Ensign contracts since March demonstrates the commercial momentum we are building and the growing demand for our technology. SMIL is another example of how we can address specific operational challenges, delivering measurable value to customers while establishing potential opportunities to expand the use of Ensign over time. Our growing presence within the Intelrad customer base, combined with the expanded capabilities of Ensign v2.3, provides a strong foundation for continued growth in recurring revenue."*

ENSIGHT Customer Agreements and Deployments – CY2026

The table below highlights Ensign's commercial progress during CY2026, including new subscription agreements, customer go-lives and the application of Ensign within major migration contracts. Migration-led engagements may provide opportunities for additional recurring revenue as customers adopt Ensign beyond their initial migration requirements:

St Jude	25 Mar 2026	Memphis, US	Ensign agreement supporting advanced imaging data search and research applications
Parkland Health	1 April 2026	Texas, US	Ensign standardisation incorporated into migration contract; opportunity for future SaaS subscription
RHCNZ Medical	12 May 2026	New Zealand	First Ensign go-live through Intelrad integration; recurring revenue commenced
Lumus Imaging	1 Jul 2026	Australia	3-year subscription; Hanging Protocols, de-identification, AI validation
Radiology Imaging Associates Colorado	11 Aug 2026	Colorado, US	Ensign deployment; 3-year recurring subscription ~US\$50k
Radiology Consultants of Iowa	27 Aug 2026	Iowa, US	Hanging Protocols; ~US\$40,000 initial ARR
Albany Medical Health System	10 Sept 2026	New York, US	3-year Ensign subscription subject to successful validation
Memorial Healthcare System	10 Sept 2026	Florida, US	3-year Ensign subscription subject to successful validation
Michigan Health-Sparrow	28 Sept 2026	Michigan, US	Ensign standardisation incorporated into migration contract; opportunity for future SaaS subscription
SCP Radiology	30 Sept 2026	South Africa	3-year Ensign subscription subject to successful validation
Southwest Medical Imaging	26 Oct 2026	Arizona, US	3-year Ensign subscription for Hanging Protocols; US\$48,000 annual subscription subject to successful validation

In addition to SMIL, Enlitic has recently secured three-year Ensign subscription agreements with Albany Medical Health System (New York), Memorial Healthcare System (Florida) and SCP Radiology (South Africa), further demonstrating the Company's growing commercial momentum. Subject to successful deployment and customer validation, these agreements are expected to contribute to recurring revenue and cash receipts. All other agreements in the table have been previously announced to ASX.

This announcement was authorised for release by the Board of Enlitic, Inc.

- ENDS -

About Enlitic

Enlitic is a software company that uses artificial intelligence to develop software products that manage medical imaging data in radiology (such as MRI, CT scans, Xray and ultrasound images) and licences such products to healthcare providers. Enlitic's products (including its current product offering and product suite under development) seek to standardise, protect, integrate, and analyse data to create the foundation of a real-world evidence platform that can improve clinical workflows, increase efficiencies, and expand capacity. Read more at enlitic.com.

Enlitic's CDIs are traded on ASX in reliance on the safe harbour provisions of Regulation S under the US Securities Act of 1933 as amended, and in accordance with the procedures established pursuant to the provisions of a no action letter dated 7 January 2000 given to ASX by the staff at the US Securities and Exchange Commission. The relief was given subject to certain procedures and conditions described in the no action letter. One of the conditions is that the issuer provides notification of the Regulation S status of its securities in communications such as this announcement.

Forward-looking statements

Certain statements made during or in connection with this announcement contain or comprise certain forward-looking statements regarding the Company, its projected cash flow, financial performance, its customer contracts and customer pipeline and product development. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, such expectations are only predictions and are subject to inherent risks and uncertainties which could cause actual values, results, performance or achievements to differ materially from those expressed, implied or projected in any forward-looking statements and no assurance can be given that such expectations will prove to have been correct.

Accordingly, results could differ materially from those set out in the forward-looking statements as a result of, among other factors, changes in economic and market conditions, delays or changes in product development and realisation of customer pipeline, changes in demand, success of business and operating initiatives, changes in the regulatory environment and other government actions, fluctuations in exchange rates and business and operational risk management.

To the maximum extent permitted by law, each of the Company, its officers, employees and advisers expressly disclaim any responsibility for the accuracy or completeness of the material contained in these forward-looking statements and excludes all liability whatsoever (including in negligence) for any loss or damage which may be suffered by any person as a consequence of any information in forward-looking statements or any error or omission. The Company undertakes no obligation to update publicly or release any revisions to these forward-looking statements to reflect events or circumstances after today's date or to reflect the occurrence of unanticipated events other than required by the applicable laws, including the ASX Listing Rules. Accordingly, you should not place undue reliance on any forward-looking statement.

Read more at enlitic.com

About Southwest Medical Imaging

Southwest Medical Imaging (SMIL) is a physician-owned and physician-led radiology practice providing diagnostic imaging and interventional radiology services across 17 outpatient centres in the Greater Phoenix metropolitan area, Arizona. Established in 1980, SMIL offers a broad range of imaging services supported by specialist radiologists and advanced medical imaging technology.

Further information:

Ben Jarvis
Six Degrees Investor Relations
Ph: 0413 150 448
Ben.jarvis@sdir.com.au